Understanding lung problems caused by collagen issues in Osteogenesis Imperfecta
Investigating pulmonary complications due to abnormal collagen/ER stress in Osteogenesis Imperfecta
This study is looking at how Osteogenesis Imperfecta (OI), which makes bones fragile, can also cause lung problems, and it aims to understand how certain changes in the body affect lung health to help improve care for people with OI.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11023042 on NIH RePORTER |
What this research studies
This research investigates how Osteogenesis Imperfecta (OI), a genetic disorder known for causing fragile bones, also leads to serious lung complications. The study focuses on the role of abnormal collagen and endoplasmic reticulum (ER) stress in affecting lung health. Using mouse models that mimic different forms of OI, researchers will explore how these factors influence lung structure, cell differentiation, and recovery from lung damage. The goal is to uncover the mechanisms behind pulmonary issues in OI to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Osteogenesis Imperfecta, particularly those experiencing pulmonary complications.
Not a fit: Patients without Osteogenesis Imperfecta or those whose lung health is not affected by collagen abnormalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and treatment options for lung complications in patients with Osteogenesis Imperfecta.
How similar studies have performed: Previous research has indicated that understanding the role of collagen in various tissues can lead to significant advancements in treatment, suggesting that this approach may yield valuable insights.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Zieba, Jennifer — University of California Los Angeles
- Study coordinator: Zieba, Jennifer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.